Movement Alert｜Argenx SE Intraday Rise 4.21%, BNP Paribas Initiates Coverage with Outperform Rating and $1,219 Target

Market Focus06-26

On June 25, Argenx SE rose 4.21% in regular trading, trading near $887.71/share, with turnover of approximately $236 million. The rally was driven by BNP Paribas initiating coverage on Argenx with an Outperform rating and a $1,219 price target, implying approximately 37% upside from current levels.

The BNP Paribas target significantly exceeds the analyst consensus mean target of $1,064.53, according to FactSet data, providing a sustained boost to market sentiment. The bullish thesis is further supported by strong fundamental developments: the company's core product Vyvgart secured FDA approval in May to expand its label to all serotypes of adult generalized myasthenia gravis patients, and first-quarter EPS of $5.52 beat the consensus estimate of $5.42, representing a 114% year-over-year increase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165133301?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165133301","market":"us","top_or_hot":-1,"title":"Movement Alert｜Argenx SE Intraday Rise 4.21%, BNP Paribas Initiates Coverage with Outperform Rating and $1,219 Target","media":"Market Focus","content":"<p><p>On June 25, Argenx SE rose 4.21% in regular trading, trading near $887.71/share, with turnover of approximately $236 million. The rally was driven by BNP Paribas initiating coverage on Argenx with an Outperform rating and a $1,219 price target, implying approximately 37% upside from current levels.</p><p>The BNP Paribas target significantly exceeds the analyst consensus mean target of $1,064.53, according to FactSet data, providing a sustained boost to market sentiment. The bullish thesis is further supported by strong fundamental developments: the company's core product Vyvgart secured FDA approval in May to expand its label to all serotypes of adult generalized myasthenia gravis patients, and first-quarter EPS of $5.52 beat the consensus estimate of $5.42, representing a 114% year-over-year increase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Argenx SE Intraday Rise 4.21%, BNP Paribas Initiates Coverage with Outperform Rating and $1,219 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Argenx SE Intraday Rise 4.21%, BNP Paribas Initiates Coverage with Outperform Rating and $1,219 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 00:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Argenx SE rose 4.21% in regular trading, trading near $887.71/share, with turnover of approximately $236 million. The rally was driven by BNP Paribas initiating coverage on Argenx with an Outperform rating and a $1,219 price target, implying approximately 37% upside from current levels.</p><p>The BNP Paribas target significantly exceeds the analyst consensus mean target of $1,064.53, according to FactSet data, providing a sustained boost to market sentiment. The bullish thesis is further supported by strong fundamental developments: the company's core product Vyvgart secured FDA approval in May to expand its label to all serotypes of adult generalized myasthenia gravis patients, and first-quarter EPS of $5.52 beat the consensus estimate of $5.42, representing a 114% year-over-year increase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1165133301","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165133301","pubTimestamp":1782404136,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Argenx SE rose 4.21% in regular trading, trading near $887.71/share, with turnover of approximately $236 million. The rally was driven by BNP Paribas initiating coverage on Argenx with an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"走势提示|Argenx SE盘中涨4.21%法巴启动覆盖评级跑赢大盘目标1219美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"On June 25, Argenx SE rose 4.21% in regular trading, trading near $887.71/share, with turnover of approximately $236 million. The rally was driven by BNP Paribas initiating coverage on Argenx with an Outperform rating and a $1,219 price target, implying approximately 37% upside from current levels.The BNP Paribas target significantly exceeds the analyst consensus mean target of $1,064.53, according to FactSet data, providing a sustained boost to market sentiment. The bullish thesis is further supported by strong fundamental developments: the company's core product Vyvgart secured FDA approval in May to expand its label to all serotypes of adult generalized myasthenia gravis patients, and first-quarter EPS of $5.52 beat the consensus estimate of $5.42, representing a 114% year-over-year increase.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165133301","isCrawlerRequest":true}